

Fanvestments Corporation
Global Investments - Global Returns
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report
Q1 - 2021

***Fanvestments FVAM Diversified Private Alternative Investment Fund
(FVAM)***

This Report describes the Fanvestments Diversified Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during and as of the 1st Quarter of 2021, and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:

Fanvestments, Corporation

Matthew Fanning – Owner / Founder / CIO / Fund Manager

mfanning@fanvestments.com

www.fanvestments.com

Twitter: @fanvestments

facebook.com/fanvestments

Instagram: @fanvestments

PRINCIPAL INVESTMENT STRATEGY

The FVAM Fund consists of a diversified portfolio of mixed asset-types, with a majority focus on equity investments ("stocks"), as well as fixed income, currency, and commodities, for the goal of price & capital appreciation, and to drive long-term positive durable returns through all types of economic and global financial cycles. FVAM's primary exposure focus is mostly within individual stocks with a long-bias, and some stock ETF exposure. The fund applies multiple strategies, from fundamental research looking at earnings, revenue, growth rates, and valuation, to analysing historical data and projecting future expectations. Combining fundamentals with technical analysis ("technical"), studying charts and price action for trends, as well as trend change, price and timeframe analysis, overbought and oversold indicators, and volume spikes leading to capitulation. The macro environment is very important as well, and will overlay macro research on top of other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find a cure for major diseases. Within Technology, to find innovation helping to shape the future, such as AI, Big Data, Cloud, Analytics, FinTech (financial technology), as well as to find the Founders that are all-in and have a sense of brilliance. Price and Returns tend to trump timeframes, but the fund does expect to hold most investments for multiple years, mid-to-long term.

The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, utilizing more of a "buy the blood" strategy - buy low-sell high, as a fundamental mindset. Fund will also seek to find opportunities within event-driven strategies, such as mergers, FDA approvals, momentum and fund flows, as well as unusual options action and potential buy-out/merger opportunities. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investing involving individual stock picking alongside minimal hedging against general market risk, as well as having low market correlation producing fund-specific returns. "401k meets Alternative Investment fund". The FVAM fund will also invest in other investment funds, indexes, and ETFs from time to time, for opportunity and to obtain that much more diversification, and to lower overall volatility and risk. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. In most hedge cases, the fund will utilize options strategies for short exposure vs outright selling short, such as index/ETF options, VIX (volatility) options, positional hedges (puts or covered calls). Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy. Such as Diversification and Position sizing - asset allocation management, always monitoring positional exposure relative to risk of that position and overall portfolio size. As well as other portfolio management strategies such as performance monitoring and risk management, constantly studying fund volatility and day-to-day statistics.

Another major objective of this fund is to begin replacing the "40" of a typical "60-40" portfolio, where 60% is towards stocks, 40% in Bonds. This bond exposure is meant to reduce volatility and risk in a portfolio, with bonds normally having a lower return. FVAM's risk management strategy and diversification should also reduce overall risk relative to stock investing, but have a much higher probability to outperform bonds and CDs. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have any intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets. An index, like the S&P 500, is also a collection of assets, with ~500 individual stock holdings. FVAM's intent is to have created its own unique investment vehicle, a diversified multi-asset fund (stocks, bonds, ETFs), with individual assets selected by Fanvestments Management, minimal market correlation, and less volatility vs market indices. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, mathematics and statistics, with the goal of perpetual improvement. Matching up technical analysis for timing with Fundamental analysis for valuation, and overlaying Macro environment research to help find Global trends and determine overall Market risk.
Make the Money Make More Money.

Q1 Highlights

For the 1st Quarter of 2021, the FVAM fund was positive, producing a 5.2% return, another strong quarter after Q4's 8.3% return. The fund was up 3.61% in January, up 1.41% in February, and up .12% in March. Since November '20 thru April '21, FVAM is up 14%. For the Quarter, the S&P 500 was up about 4.9% (with the index down -1% in January, vs FVAM up 3.6%). The ACWX etf, which tracks stocks around the world excluding the United States, was up about 4.3% for the quarter. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure like bonds and credit, currency and/or commodity, lower risk & volatility, and with equity exposure around 86% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock index. Another reference point, a more relative and important comparative benchmark for the fund, is Warren Buffett's Berkshire Hathaway. Using the BRK/b shares, Berkshire was up ~11% for the 1st quarter of 2021, although only finishing the full year of 2020 up about 2%. FVAM finished 2020 up just over 10%, with the 1st quarter 2020 down -1.3%, while this Q1 2021, the fund finished up 5.2%.

The fund's top performing investments at the end of the 1st quarter were Tilray (TLRY), Vir Biotechnology (VIR), and Baidu (BIDU) as the top three. Following them up were DraftKings (DKNG), Spirit Aerosystems (SPR), and Canopy Growth (CGC), with Cronos Group (CRON), Weight Watchers (WW), Citibank (C), and Toll Brothers (TOL) rounding out the top 10 investments for the quarter. Vir Biotech, Tilray, Baidu, DraftKings, Spirit Aerosystems were all sold in full for sizable gains. As much as buying a stock that goes up gets much attention, selling a position with sizable profits, especially right before stock goes lower, is equally as important. Baidu, sold in full between \$250 to \$307, hit a high at \$354 in February, quickly went as low as \$175 by mid-March. Vir Biotech, sold in full between \$70 and as high as \$115, went drastically lower to \$35 by early-march. Tilray, sold in full as high as \$71, went down to \$20 by the end of March. Draftkings, sold in full between \$62 to \$71, was down to \$40 by early May. Fund also sold out of Telsa between \$700 to \$800, which originally bought in the mid-\$400s, currently holding around \$600. In the quarter, the fund increased investments in World Wrestling (WWE), Salesforce (CRM), Coupang (CPNG), Vertex Pharma (VRTX), and initiated a new position in crypto currency Ethereum using GrayScales fund, \$ETHE. Fund initiated new core positions in Citibank (C), Weight Watchers (WW), Coupang (CPNG), as well as World Wrestling Entertainment (WWE), all intended for longer-term investments. The Fund began buying Coupang in March, one of the largest e-commerce companies in Asia, somewhat like the Amazon of South Korea, and currently has an average cost just below \$44/share. Coupang went public via IPO in early March in the high 60's, and pulled back towards \$30 after its 1st earnings report. In Q1, Total Net Revenues grew 74% to 4.2 billion, with gross profit at \$733 million, a 70% increase year-over-year, although Coupang is not currently net profitable. Target price at \$115 going out 1-2 years, using an average of 10x Sales which gets \$97, and 70X future EPS (1x PEG) which gets stock to \$134.

Can read more about Coupang here : [Coupang Q1 Earnings](#)

Looking into Q2 2021, new positions were initiated in Advanced Micro Devices (AMD) and Bumble (BMBL). Looking to add semiconductor exposure to the fund as the need for chips for devices explodes, the fund added AMD just above \$77/share. Current price-target looking out 1-2 years at \$112, about 40-50% upside. Using an average of 8x net sales, which would equal \$106/share, and 50x PE, which would get the stock price to \$118. AMD reached a high just above \$99 this past January. AMD is also in the process of acquiring Xilinx for \$35 Billion.


Can read more about AMD here: [AMD Investor Presentation](#)

Bumble, an online dating and social networking platform, came public this year in February, hit a high close to \$85, and went as low as \$39 in May. Fund began buying in April, with an average cost slightly below \$54. Bumble grew their revenue by 44% in Q1 vs Q1-2020, to \$171 million, with total paying users up by 30% to 2.8 million. Price target looking out a year at \$76. Longer term price target at \$148, if compared to its top competitor Match.com which is currently priced at 18x Sales. This would give Bumble a market cap of \$18 billion, still just a third of Match.com's market cap of 45 billion.


Can read more about Bumble here: [Bumble \(BMBL\) Q1 Earnings](#)

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (*Portfolio Data as of April 2021)

High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's individual stock exposure. Currently, the heaviest focus of that exposure is allocated towards the Healthcare and Biotech sector, as well as Consumer Discretionary.




Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM)


FVAM fund, 1st Quarter 2021 , Weekly




FVAM fund, One-Year (April 2020 thru April 2021), Weekly




FVAM fund (green) vs SPX (S&P 500, orange), Q1 2021, weekly




FVAM fund (green) vs SPX (S&P 500, gray), Q1 2021, Daily




FVAM fund (green, left) vs BRK/b (blue, right), 2021 Full-Year (thru April), Weekly
 (\$BRK-B : Berkshire Hathaway B-shares)




FVAM fund (green, left) vs BRK/b (blue, right), Q1 2021, Daily




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, Q4 2020 thru Q1 2021
(excess: positive = outperformance, negative = underperformance)




FVAM vs BRK/b and relative return (FVAM vs BRK/b), weekly, Q1 2021
(excess, positive = outperformance, negative = underperformance)




FVAM (Green) vs S&P500 vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) , 1st Quarter - 2021




FVAM (green) vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets), Q1 - 2021




FVAM (top) compared to SPX (S&P 500, bottom), Q1 2021 - Weekly




FVAM vs SPX and relative return (FVAM vs SPX), Q1 - 2021
 (*excess return shows FVAM vs SPX, shows by how much FVAM is outperforming or underperforming the S&P 500)




FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q1




FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$ACWX (World Index x-US), Daily, Full-Year (thru April)




FVAM (green) vs EEM (Emerging Markets) , Q1 2021, Weekly




FVAM (green) vs LQD (Investment Grade Corporate Bonds), Full-Year (thru April, Weekly




S&P 500 (orange) vs ACWX (World Index minus U.S.), Q1 2021, Weekly



FVAM vs ACWI (World Index), with Relative Return (excess return), Q1 2021, Weekly




FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500 (orange),
 Last 6 months (thru April 2021), monthly returns



Reference 1: FVAM Fund Performance Stats (showing view of September 2021, FVAM vs SPX, Statistics)

The data below, displaying just November 2021 in this example, shows performance statistic data maintained daily, showing the FVAM fund vs the S&P 500, even though FVAM is not trying to match or mimic the actual underlying stocks, within the S&P 500, or match the performance of the index. Data shows performance for FVAM, performance for the S&P 500 (\$SPX), as well as relative performance and mathematical statistics (showing risk & volatility). The chart displays daily performance for both FVAM (green) and SPX (blue). Another very important factor for FVAM is to be less volatile than the SPX, which is being analyzed using Statistics, such as Standard Deviation (SDDEV). Excess Return shows relative performance between FVAM and \$SPX (outperformance positive, or underperformance negative). Index C shows plus or minus on a progressive (rolling) basis through the month. The "match (golf)" column also shows that progressive relative performance, but for larger outperformance or underperformance, using a 50bp (+/- 0.5%) differential.

January 2021



*SPX (S&P500 index), BRK/B (Berkshire Hathaway) and any other index/fund/investment vehicles' performance using internal data tracking and data from multiple public internet sources, "non-official" data only.

Heat Map for the NASDAQ 100 Index, showing each stock within that index/sector along with its relative size and weight compared to the overall index (**larger the block size the larger percentage that stock makes up within the index**) (*as of May 2021)



